drugset / Trial / NCT00603330

Summary

The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD. Part 2: Poor graft function (PGF) Part 3: Low or falling donor T-cell chimerism after allogeneic HCT. This is a multicenter phase II study examining the feasibility and efficacy of this approach.

Timeline

Start
2008-01
Primary completion
2024-08
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Other
Subject mesenchymal stem cells Cell therapy 4e+06 cells/kg Other